Alector Reports Third Quarter 2024 Financial Results and Provides Business Update
Rhea-AI Summary
Alector reported Q3 2024 financial results with collaboration revenue of $15.3 million and a net loss of $42.2 million. The company maintains a strong cash position of $457.2 million, providing runway through 2026. Key clinical updates include: the INVOKE-2 Phase 2 trial data for AL002 in early Alzheimer's disease expected in 2024, with 98% participant retention in long-term extension; INFRONT-3 Phase 3 trial for latozinemab in FTD-GRN progressing with enrollment completed; and PROGRESS-AD Phase 2 trial for AL101 reaching over one-third of target enrollment. The company reaffirmed 2024 guidance with expected collaboration revenue of $60-70 million.
Positive
- Strong cash position of $457.2 million providing runway through 2026
- 98% retention rate in INVOKE-2 trial long-term extension
- Potential $250 million payment from AbbVie upon option exercise for AL002
- Collaboration revenue increased to $15.3 million from $9.1 million YoY
- Net loss per share improved to $0.43 from $0.53 YoY
Negative
- Net loss of $42.2 million in Q3 2024
- Increased R&D expenses to $48.0 million from $46.3 million YoY
- G&A expenses increased to $15.8 million from $13.4 million YoY
News Market Reaction – ALEC
On the day this news was published, ALEC gained 7.63%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Data from INVOKE-2, evaluating TREM2 agonist candidate AL002 in patients with early Alzheimer’s disease (AD), on track for 2024
Participant baseline characteristics in pivotal INFRONT-3 Phase 3 trial suggest a representative study population for testing the effects of latozinemab in frontotemporal dementia with a progranulin gene mutation (FTD-GRN)
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today reported third quarter 2024 financial results and recent portfolio and business updates. As of September 30, 2024, Alector’s cash, cash equivalents, and investments totaled
“We continue to make meaningful progress advancing our innovative pipeline of product candidates and remain on track to report data in 2024 from the INVOKE-2 Phase 2 trial of AL002, the most advanced TREM2 candidate in clinical development for early Alzheimer’s disease,” said Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector. “We believe that increased TREM2 signaling via AL002 may recruit disease-fighting microglia to broadly counteract the progression of Alzheimer’s disease. INVOKE-2 is designed to provide meaningful insights into AL002’s potential benefits across a combination of clinical and functional endpoints, as well as imaging and fluid biomarkers. We also believe that the broad mechanism of AL002 may have the potential to deliver potent and durable therapeutic benefits, both as a standalone therapy and in combination with anti-amyloid beta antibodies.”
Dr. Rosenthal continued, “For our progranulin franchise, we recently reported the patient baseline characteristics for our INFRONT-3 Phase 3 clinical trial of latozinemab in frontotemporal dementia with a progranulin gene mutation, suggesting a representative study population in this indication. We are approaching a top-line data readout for INFRONT-3 in late 2025/early 2026. Additionally, PROGRESS-AD, the Phase 2 trial of AL101/GSK4527226 in early Alzheimer’s disease, has reached more than one-third of its target enrollment. It is an exciting time at Alector, and we are well positioned to advance our proprietary pipeline of novel immuno-neurology drugs.”
Sara Kenkare-Mitra, Ph.D., President and Head of Research and Development at Alector, added, “We are actively advancing our Alector Brain Carrier, ABC, a proprietary versatile blood-brain barrier technology, and we are strategically leveraging this platform across our portfolio. We believe our ABC technology may advance treatment of neurodegenerative diseases by potentially enabling improved delivery of our therapeutics to the brain.”
Recent Clinical Updates
Immuno-Neurology Portfolio
TREM2 Program (AL002) Being Developed in Collaboration with AbbVie
- The results of the INVOKE-2 Phase 2 clinical trial of AL002 are expected in 2024. INVOKE-2, a randomized, double-blind, placebo-controlled, dose-ranging study, is designed to assess the efficacy and safety of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). AL002 is a novel investigational humanized monoclonal antibody (mAb) that is designed to bind to TREM2 to increase TREM2 signaling and, thereby, is hypothesized to improve the functionality of microglia. It is the most advanced TREM2 agonist product candidate in clinical development worldwide.
98% of eligible participants who completed the planned treatment period of INVOKE-2 have elected to participate in the long-term extension (LTE) study.
- In October 2024, Alector published a manuscript titled “Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer’s disease” in Alzheimer’s Research & Therapy. The publication outlines preclinical and INVOKE-1 Phase 1 study results, demonstrating that AL002 engaged TREM2, and induced pharmacodynamic biomarker changes associated with microglial proliferation, survival, and phagocytic activity in a dose-dependent manner.
- AbbVie has an exclusive option to globally develop and commercialize AL002. Alector will deliver a data package resulting from the INVOKE-2 study to AbbVie for their evaluation. AbbVie’s exercise of its option would prompt a
$250 million payment to Alector.
Progranulin Programs (latozinemab (AL001) and AL101/GSK4527226) Being Developed in Collaboration with GSK
- The pivotal, randomized, double-blind, placebo-controlled INFRONT-3 Phase 3 clinical trial of latozinemab targeting frontotemporal dementia with a progranulin gene mutation (FTD-GRN) is ongoing and on track, with enrollment completed in October 2023 and a treatment duration of 96 weeks. Latozinemab is a novel investigational human mAb that aims to increase progranulin (PGRN) levels by inhibiting sortilin and is the most advanced PGRN-elevating candidate in development for the treatment of FTD-GRN.
- In September 2024, Alector presented a poster highlighting the patient baseline characteristics for INFRONT-3 at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024). Notably, the baseline characteristics of symptomatic INFRONT-3 participants, including age, Clinical Dementia Rating scale plus National Alzheimer’s Disease Coordinating Center Frontotemporal Lobar Degeneration Sum of Boxes (CDR® plus NACC FTLD-SB) score and neurofilament light chain (NfL) levels, were representative of the broader FTD-GRN registry population, based on available registry data. Additionally, Alector shared findings from the FTD Caregiver Survey and FTD Insights Survey, highlighting the challenges faced by caregivers of individuals living with FTD.
- PROGRESS-AD, a global, randomized, double-blind, placebo-controlled Phase 2 clinical study evaluating AL101/GSK4527226 in early AD has reached more than one-third of its target enrollment of 282 participants, with dosing initiated in February 2024. AL101 is an investigational human mAb designed to block and downregulate the sortilin receptor to elevate the level of PGRN in the brain in a manner that is similar to investigational latozinemab but with different pharmacokinetic and pharmacodynamic properties.
Early Research Pipeline
- Alector continues to advance its Alector Brain Carrier (ABC), a proprietary, versatile blood-brain barrier technology platform, which is being applied selectively to the company’s next-generation product candidates and research pipeline. The technology platform enables customization of affinity, valency, and format to optimize effector function and half-life in preclinical models. Alector is applying its ABC technology, combined with its expertise in immuno-neurology, to work on novel targets and develop first or best-in-class therapeutics.
Third Quarter 2024 Financial Results
Revenue. Collaboration revenue for the quarter ended September 30, 2024, was
R&D Expenses. Total research and development expenses for the quarter ended September 30, 2024, were
G&A Expenses. Total general and administrative expenses for the quarter ended September 30, 2024, were
Net Loss. For the quarter ended September 30, 2024, Alector reported a net loss of
Cash Position. Cash, cash equivalents, and investments were
2024 Guidance. The Company continues to anticipate collaboration revenue to be between
About Alector
Alector is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector has discovered and is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable rejuvenated immune cells to counteract emerging brain pathologies. Alector’s immuno-neurology product candidates are supported by biomarkers and seek to treat indications, including Alzheimer’s disease and genetically defined frontotemporal dementia patient populations. Alector is headquartered in South San Francisco, California. For additional information, please visit www.alector.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements regarding our business plans, business strategy, product candidates, blood-brain barrier technology platform, planned and ongoing preclinical studies and clinical trials, anticipated timing of and detail regarding release of data for INVOKE-2 and INFRONT-3, expected milestones, expectations of our collaborations, expectations of our interactions with regulatory authorities, and financial and cash guidance. Such statements are subject to numerous risks and uncertainties, including but not limited to risks and uncertainties as set forth in Alector’s Quarterly Report on Form 10-Q filed on November 6, 2024, with the Securities and Exchange Commission (“SEC”), as well as the other documents Alector files from time to time with the SEC. These documents contain and identify important factors that could cause the actual results for Alector to differ materially from those contained in Alector’s forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and Alector specifically disclaims any obligation to update any forward-looking statement, except as required by law.
| Selected Consolidated Balance Sheet Data (in thousands) | ||||||
| September 30, | December 31, | |||||
| 2024 | 2023 | |||||
| Cash, cash equivalents, and marketable securities | $ | 457,202 | $ | 548,861 | ||
| Total assets | 516,023 | 621,827 | ||||
| Total current liabilities (excluding deferred revenue) | 87,098 | 94,973 | ||||
| Deferred revenue (including current portion) | 248,202 | 293,820 | ||||
| Total liabilities | 397,090 | 487,669 | ||||
| Total stockholders’ equity | 118,933 | 134,158 | ||||
| Consolidated Statement of Operations Data (in thousands, except share and per share data) | ||||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||||
| Collaboration revenue | $ | 15,342 | $ | 9,109 | $ | 46,318 | $ | 81,872 | ||||||||||
| Operating expense: | ||||||||||||||||||
| Research and development | 47,998 | 46,328 | 139,479 | 144,392 | ||||||||||||||
| General and administrative | 15,778 | 13,364 | 44,587 | 41,767 | ||||||||||||||
| Total operating expenses | 63,776 | 59,692 | 184,066 | 186,159 | ||||||||||||||
| Loss from operations | (48,434 | ) | (50,583 | ) | (137,748 | ) | (104,287 | ) | ||||||||||
| Other income, net | 6,214 | 7,360 | 20,853 | 18,876 | ||||||||||||||
| Net loss before income tax | (42,220 | ) | (43,223 | ) | (116,895 | ) | (85,411 | ) | ||||||||||
| Income tax expense | — | 1,252 | 80 | 3,546 | ||||||||||||||
| Net loss | $ | (42,220 | ) | $ | (44,475 | ) | $ | (116,975 | ) | $ | (88,957 | ) | ||||||
| Net loss per share: | ||||||||||||||||||
| Net loss per share, basic and diluted | $ | (0.43 | ) | $ | (0.53 | ) | $ | (1.22 | ) | $ | (1.07 | ) | ||||||
| Shares used in computing net loss per share basic and diluted | 97,519,595 | 83,927,961 | 96,007,105 | 83,513,954 | ||||||||||||||
Alector Contacts:
Alector
Katie Hogan
202-549-0557
katie.hogan@alector.com
1AB (media)
Dan Budwick
973-271-6085
dan@1abmedia.com
Argot Partners (investors)
Laura Perry
212-600-1902
alector@argotpartners.com
FAQ
What were Alector's (ALEC) Q3 2024 financial results?
When will Alector (ALEC) report INVOKE-2 trial results for AL002?
What is Alector's (ALEC) financial guidance for 2024?
What is the status of Alector's (ALEC) INFRONT-3 Phase 3 trial?
